SCHEMBL12819922

SCHEMBL12819922

N#Cc1ccc(-c2c3n(c4ccccc24)CCCC3)cc1F

nearest known ligand 0.47

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 7/20 0.47
CYP11B2 P19099 7/20 0.47
PDE4A P27815 3/20 0.42
PDE4C Q08493 3/20 0.42
PDE4D Q08499 2/20 0.42
HTR2A P28223 1/20 0.41
HTR2C P28335 1/20 0.41
AR P10275 1/20 0.37
PDE4B Q07343 2/20 0.37
EGLN2 Q96KS0 2/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
TRPV4 Q9HBA0 1/20 0.36
KDM1A O60341 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12820359 0.80 CYP11B1 (0.44) CYP11B1CYP11B2PDE4APDE4CPDE4D
SCHEMBL12819925 0.76 PRKCQ (0.39) PDE4APDE4CHTR2AHTR2CAR
SCHEMBL7601620 0.73 CYP11B1 (0.45) CYP11B1CYP11B2PDE4APDE4CPDE4D
SCHEMBL11250873 0.67 GAA (0.52)
SCHEMBL14555724 0.66 CYP11B2 (0.65) CYP11B1CYP11B2EGLN2TRPV4
SCHEMBL19755354 0.66 CNR2 (0.37) CYP11B1CYP11B2PDE4APDE4CPDE4D
SCHEMBL15248404 0.66 KDM4E (0.45) CYP11B1CYP11B2
SCHEMBL18297999 0.66 CYP11B2 (0.67) CYP11B1CYP11B2TRPV4
SCHEMBL4580915 0.65 EGLN2 (0.48) CYP11B1CYP11B2EGLN2KDM1A
SCHEMBL1514257 0.65 CYP11B1 (0.78) CYP11B1CYP11B2TRPV4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012126084-A1 HSP-90 BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND THEIR USE IΝ THE TREATMENT AND PREVENTION OF FUNGAL INFECTIONS PHARMASCIENCE INC. (CA) 2012-09-27 WO disclosed
WO-2011035417-A1 HSP-90 BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND THEIR USE FN THE TREATMENT OF AUTOIMMUNE AND INFLAMMATORY DISEASES AEGERA THERAPEUTICS INC. (CA) 2011-03-31 WO disclosed